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The enterohemorrhagic Escherichia coli (EHEC) O91:H21 isolates B2F1 and H414-36/89 are virulent in an
orally infected streptomycin-treated mouse model. Previous studies demonstrated that B2F1 and H414-36/89
grow to high levels in mucus isolated from the mouse small intestine and colon and that growth in small-
intestinal mucus is related to virulence. We measured the levels of Shiga-like toxins (SLTs) SLT-IIvha and
SLT-IIvhb produced by B2F1 after growth in Luria-Bertani (LB) broth supplemented with mouse intestinal
mucus by assaying the cytotoxicity of culture supernatants on Vero cells. Culture supernatants from B2F1
grown in mouse intestinal mucus, but not EHEC strains that produce SLT-II or SLT-IIc, were approximately
35- to 350-fold more toxic for Vero cells than supernatants from B2F1 grown in LB broth. This increased
toxicity was not reflected by a concomitant increase in SLT antigen content. Furthermore, when culture
supernatants from B2F1 or K-12 strains carrying plasmids encoding SLTs cloned from H414-36/89 or purified
SLT-IIvhb from B2F1 were incubated with mouse intestinal mucus, the samples exhibited greater cytotoxicity
than when they were incubated with N-2-hydroxyethylpiperazine-N*-2-ethanesulfonic acid (HEPES) buffer
alone. These toxin preparations also showed increased cytotoxicity after incubation with human colonic mucus.
In contrast, culture supernatants from LB-grown EHEC isolates that produced SLT-I, SLT-II, SLT-IIc, or
SLT-IIe did not show increased cytotoxicity after incubation with mouse or human intestinal mucus. The A
subunits of purified SLT-II and SLT-IIvhb that had been treated with mouse intestinal mucus or trypsin were
cleaved to A1 fragments by the mucus, but trypsin-mediated cleavage, unlike treatment with mouse intestinal
mucus, did not result in increased Vero cell cytotoxic activity. This finding implies that the increased cyto-
toxicity of SLT-IIvhb detected after incubation with mucus is probably not due to cleavage of the A subunit into
the A1 and A2 fragments. Taken together, these results indicate that mouse or human intestinal mucus directly
activates SLT-II-related toxins from B2F1 and H414-36/89 and suggest that toxin activation may explain the
low 50% lethal doses of B2F1 and H414-36/89 in streptomycin-treated mice.
Enterohemorrhagic Escherichia coli (EHEC) strains cause
food-borne hemorrhagic colitis and the hemolytic uremic syn-
drome. All EHEC strains maintain a large plasmid and pro-
duce one or more Shiga-like toxins (SLTs; also called Vero
toxins), and some express the product of the eaeA gene, in-
timin. SLTs are believed to be involved in the production of
the more serious sequelae of both hemorrhagic colitis and the
hemolytic uremic syndrome (5, 21, 34). SLTs are potent toxins
that consist of a single A subunit and a pentamer of B subunits
(21). The B subunit is responsible for binding the toxin to the
eukaryotic cell receptor Gb3 (11, 14). The A subunit cleaves an
adenine residue from the 28S rRNA within the 60S ribosome
and, consequently, halts protein synthesis in the target eukary-
otic cell (4, 26). The A subunit has a trypsin-sensitive cleavage
site near the C terminus which, when nicked, results in the
formation of an approximately 28-kDa peptide that has the
enzymatic activity of the toxin and an approximately 4-kDa A2
peptide that links the A1 peptide to the B pentamer (6). The
A1 and A2 peptides remain linked to each other by the single
disulfide bond present in the A subunit.
Our laboratory uses a streptomycin-treated, orally infected
mouse model to study EHEC infection (36). Mice fed certain
strains of EHEC or K-12 strains carrying high-level toxin-
producing plasmids become lethargic, occasionally exhibit
hind-limb paralysis, stop eating, and die within 4 to 10 days of
infection (depending on the size of the inoculum) (15, 36, 37).
Death of the mice is due to severe bilateral tubular necrosis of
the kidney (15, 37). The capacity of an E. coli isolate to cause
a lethal mouse infection requires that the mouse intestine
become colonized by the bacterium and that the strain produce
an SLT of the II type (15). We previously reported that the
O91:H21 EHEC isolates B2F1 (produces SLT-IIvhb and SLT-
IIvha) and H414-36/89 (contains one copy of slt-II and two
copies of slt-II-variant genes) are the most virulent (oral 50%
lethal dose [LD50] of ,10 CFU) of the EHEC strains that we
have tested in the streptomycin-treated mouse (15). In that
same study, we showed that the capacity of B2F1 to grow in
mouse small-intestinal mucus in vitro correlates with, but is not
sufficient to explain, the low LD50 of B2F1 (15). Indeed, EHEC
isolate E32511/HSC replicates as well as B2F1 in mouse small-
intestinal mucus but has an oral LD50 of 10
10 CFU. We also
concluded that SLT production is absolutely required for the
marked virulence of B2F1 in this model, on the basis of the
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observation that passive immunization of infected mice with
anti-SLT-II but not anti-cholera toxin antibodies protects the
mice from lethality and death but not from colonization by
B2F1 (15). In this report, we sought to further define the
mechanism of B2F1 virulence and found that mouse and hu-
man intestinal mucus significantly increased the toxicity of
SLTs produced by mouse-virulent B2F1 for Vero cells.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains and plasmids used in this study are
listed in Table 1. B2F1 is an O91:H21 strain that produces SLT-IIvha and
SLT-IIvhb, maintains the EHEC large plasmid, is eaeA negative, and was iso-
lated from a patient with the hemolytic uremic syndrome (15, 32). SLT-IIvha and
SLT-IIvhb were recently classified as SLT-IIc toxins (38), but we will refer to
them as SLT-IIvhb and SLT-IIvha for clarity in this report.
Cytotoxicity assay. The cytotoxicity of culture supernatants or sonic lysates for
Vero cells was determined as described previously (7, 28). Briefly, samples were
serially diluted in tissue culture medium. One hundred microliters of each dilu-
tion was added to individual wells of a 96-well microtiter plate which contained
approximately 104 Vero cells in 100 ml of medium. The tissue culture plates were
then incubated at 378C in the presence of 5% CO2 for 48 h and then fixed and
stained with crystal violet. The intensity of color of the fixed and stained cells was
measured with a Titertek Multiscan MC reader at 620 nm. The 50% cytotoxic
dose (CD50) was determined as the reciprocal of the highest dilution that caused
50% Vero cell death compared with control untreated cells.
Isolation of mouse intestinal mucus. Intestinal mucus was isolated from 22- to
24-g male CD-1 mice essentially as described previously (36). The mice were
pretreated with streptomycin (5 g/liter) in their drinking water to eliminate
facultative anaerobes from the intestine. Food was removed from the mice 18 h
prior to mucus isolation to reduce the amount of fecal material. The mice were
sacrificed, and their intestines were removed the following day. Fecal material
was gently pushed out of the intestines and discarded. The mucus was then
scraped into HEPES (N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid; 2.4
g/liter) buffered to pH 7.4. The mucus sample was clarified by centrifugation at
12,0003 g for 10 min followed by centrifugation for 15 min at 27,0003 g. Mucus
recovered in this way is free of aerobes, as indicated by the lack of viable
organisms after plating the mucus on Luria-Bertani (LB) (17) agar plates. Total
protein content of the mucus was measured with a bicinchoninic acid protein
assay kit (Pierce, Rockford, Ill.).
Isolation of human colonic mucus. Human colonic mucus was isolated from
the pooled effluent obtained after flexible sigmoidoscopies or colonoscopies
performed on at least eight patients. Such pooled intestinal effluent was collected
on two separate occasions. The pooled effluent was stored on ice, and the upper
layer of dilute effluent was removed and discarded. The colonic mucus, which
settled to the bottom of the container, was further separated from the effluent by
a 10-min centrifugation at 12,000 3 g. The protein concentration of the mucus
preparation was then measured with a bicinchoninic acid protein assay kit
(Pierce). Human colonic mucus was diluted with HEPES buffer to give a final
mucus protein concentration of 1 mg/ml in the activation experiments.
Effect of mouse intestinal mucus on growth of EHEC in vitro and on SLT
cytotoxicity. LB broth was supplemented with mouse mucus at a final mucus
protein concentration of 1 or 2 mg/ml. The mucus-supplemented LB or un-
supplemented LB broth tubes were inoculated from a diluted overnight culture
to achieve a final concentration of 102 CFU/ml and incubated in a shaking water
bath at 378C for 20 h. The CFU per milliliter of culture were determined by
making serial dilutions of the sample into phosphate-buffered saline (PBS) and
plating the dilutions onto LB agar. Additionally, an aliquot was removed from
the culture for subsequent assessment of Vero cytotoxic activity. The bacteria
were removed from the sample by centrifugation at 27,000 3 g for 15 min, and
the clarified supernatant was stored at 2208C. For comparison of the cytotoxic
activities of EHEC O157:H7 strain 86-24 and B2F1 grown in LB supplemented
with mucus, supernatants or sonically disrupted lysates of the cultures were
prepared. Cytotoxicity data generated in the experiments in which the EHEC
strains were grown in LB broth or LB with mouse intestinal mucus were nor-
malized for growth by dividing the CD50 per milliliter by the CFU per milliliter
and multiplying by 1010. The effect of growth of bacteria in the presence of mucus
was then calculated as the ratio of the CD50 per CFU after growth in LB with
mouse intestinal mucus to the CD50 per CFU after growth in LB alone.
SLT antigen level determination. SLT antigen levels were determined by an
enzyme-linked immunosorbent assay (ELISA) kit (Meridian Diagnostics, Inc.,
Cincinnati, Ohio) according to the manufacturer’s instructions. Immunoblotting
was used as an alternative method as follows. Culture supernatants were con-
centrated with a Centriprep-30 (Amicon, Beverly, Mass.) column and then sub-
jected to native polyacrylamide gel electrophoresis (PAGE) with a continuous
10% gel. The proteins separated on the gel were transferred to BAS-NC nitro-
cellulose (Schleicher & Schuell Inc., Keene, N.H.) by electroblotting. The nitro-
cellulose was then blocked with 5% nonfat dry milk in Tris-buffered saline that
contained 0.1% Tween 20 (TBST). After the blocked nitrocellulose filter was
washed with TBST, the filters were incubated with polyclonal antisera to B2F1
toxins (32) at a dilution of 1:3,300. The antibody-treated filters were then washed
extensively with TBST and incubated with a horseradish peroxidase-conjugated
donkey anti-rabbit immunoglobulin antiserum (Amersham, Arlington Heights,
Ill.) at a dilution of 1:1,000. Antigen-antibody complexes were detected by incu-
bating the blot with enhanced chemiluminescence Western blot (immunoblot)
detection reagents (Amersham) and then exposing the blot to X-Omat film
(Eastman Kodak Co., Rochester, N.Y.).
Cytotoxic activity of crude SLT preparations treated with mouse or human
intestinal mucus. Bacterial strains were grown overnight in LB broth. The cul-
tures were centrifuged at 12,000 3 g for 10 min to remove the bacteria. The
supernatant was sterilized by passage through a 0.45-mm-pore-size filter. The
sterile supernatant was then incubated at 378C for 2 to 4 h with HEPES buffer
alone or in mouse proximal-small-intestinal mucus (MPSIM) or human colonic
mucus that was adjusted to a final concentration of 1 mg/ml. The CD50 per
milliliter of sample was then determined on Vero cells as described above.
Toxin purification and treatment of purified toxin with mouse or human
mucus and/or trypsin. SLT-II and -IIvhb were purified as described previously
(16). SLT-I was purified by the same method (16), with the following modifica-
tions. E. coliDH5a(pLPSH3), an SLT-I-producing strain, was grown in LB broth
with 100 mg of ampicillin per ml. Plasmid pLPSH3 is a derivative of pNAS10 in
vector pBR329 (30). The antibody used for the affinity column was 13C4, an
anti-SLT-I B subunit monoclonal antibody (31).
Purified toxin was incubated for 1 to 2 h at 378C with a HEPES buffer control,
a bovine serum albumin (BSA) control, MPSIM, or human colonic mucus at a
final concentration of 1 mg/ml. The CD50 of the treated toxin per milliliter was
then measured on Vero cells as described above. For the trypsin treatment
studies, purified toxin was incubated with trypsin at a final concentration of 20
mg/ml for 2 h at 378C. Trypsin inhibitor was then added to a final concentration
of 28 mg/ml, and the cytotoxicity of the sample was determined on Vero cells.
Purified treated and untreated toxin preparations were subjected to sodium
dodecyl sulfate (SDS)-PAGE (12% gel) and then to the immunoblot procedure
described above.
Mouse feeding studies. The mouse feeding studies were done essentially as
described previously (15, 36). Male 22- to 24-g CD-1 mice were treated with
streptomycin sulfate (5 g/liter) in their drinking water 18 h prior to feeding. Food
was removed from the mice 15 to 18 h prior to feeding. The bacterial strain to be
fed was grown with aeration overnight in LB broth. The bacterial strain was then
diluted into 20% sucrose, and the mice were fed the approximate dose in 0.8 ml.
The actual dose fed was determined by colony count as described above. The
experiments reported here were conducted according to the principles set forth
by the National Institutes of Health (20).
Bacterial counts, associated Vero cell activity, and SLT antigen levels in
mouse intestinal contents, serum, and kidney extracts after feeding of B2F1 to
streptomycin-treated mice. B2F1 was fed at a dose of approximately 4 3 109
CFU to two groups of five mice each as described above. After 9 hours or 4 days,
blood was collected by exsanguination of the mice following anesthesia with
metofane. Mice were sacrificed, and the kidneys were removed, placed in cold
PBS, and disrupted in a stomacher. Next, the entire cecum, a 10-cm segment
from the distal small intestine, the colon, and the kidney were placed individually
into cold PBS and disrupted in a stomacher. The CFU per sample were deter-
mined by plate count on LB agar as described above. Because these mice had
been treated with streptomycin to remove normal bacterial flora, essentially pure
cultures of the streptomycin-resistant bacterial inoculum were recovered from
the intestines. After removal of the bacteria from the homogenate of the intes-
TABLE 1. Strains and plasmids used or described in this study
Strain Serotype SLT type(s)
Strain from
which SLT
originated
Reference
or source
B2F1 Sra O91:H21 IIvha, IIvhb 10
H414-36/89 Sr O91:H21 II, II variantb 2
E32511 O157:H2 II, IIc CDCc
E32511/HSC Sr O157:H2 IIc 9
86-24 O157:H7 II 8
933D O157:H7 I CDC
S1191 O139 IIe 18
DH5a(pSQ544) Rough IIvhb B2F1 16
DH5a(pSQ343) Rough IIvha B2F1 16
DH5a(pSQ135) Rough II variant H414-36/89 16
DH5a(pSQ47) Rough II variant H414-36/89 16
DH5a(pSQ81) Rough II H414-36/89 16
DH5a(pCKS120) Rough IIc E32511 16
DH5a(pCKS123) Rough II E32511 16
a Sr, streptomycin resistant.
b Strain H414-36/89 has two copies of an SLT-II-variant-type toxin (15).
c CDC, Centers for Disease Control and Prevention.
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tinal segment by centrifugation at 12,000 3 g for 10 min followed by centrifu-
gation at 27,0003 g for 15 min, the level of Vero cell cytotoxic activity associated
with the clarified sample or from sonic lysates of the bacterial pellet resuspended
in an equal volume of PBS was determined. SLT antigen levels were measured
in serum (separated from clotted blood), kidney, and intestinal samples by an
ELISA kit as described above.
Comparison of mouse colonization capacities of B2F1 and E32511/HSC. To
compare intestinal colonization of strain B2F1 with that of strain E32511/HSC,
approximately 5 3 106 organisms of each strain were fed to a group of five mice
as described above. After 14 h of infection, the intestines were removed and the
number of bacteria per segment was determined as described above.
RESULTS
Cytotoxicity of B2F1 culture supernatants after growth in
mouse intestinal mucus. B2F1 grows equally well in (i) HEPES
buffer supplemented with mouse intestinal mucus isolated
from any site along the mouse intestinal tract (17), (ii) LB
broth (data not shown), and (iii) LB broth supplemented with
mouse intestinal mucus (data not shown). Because growth in
mouse intestinal mucus correlates with but is not sufficient to
explain the striking virulence of B2F1 in orally infected, strep-
tomycin-treated mice, we asked whether there might be an
increase in the cytotoxicity for Vero cells of B2F1 culture
supernatants after growth in LB supplemented with mouse
small-intestinal mucus compared with growth in LB. Prelimi-
nary experiments showed that there was an increase in the level
of cytotoxicity in the supernatant of cultures of B2F1 grown in
LB broth supplemented with mucus isolated from any site
along the small intestine (data not shown). Because growth of
EHEC in MPSIM correlates with virulence, we used MPSIM
for most of our remaining studies. The average increase in
cytotoxicity of supernatants from B2F1 grown in LB with MP-
SIM added compared with supernatants from B2F1 grown in
LB broth alone is shown in Table 2. Mouse intestinal mucus
alone was not toxic for Vero cells at the levels used in these
experiments.
Cytotoxicity of culture supernatants or bacterial lysates of
EHEC isolate B2F1, 86-24, or E32511/HSC after growth in
mouse intestinal mucus. We next determined whether EHEC
strains E32511/HSC and 86-24 exhibited similar increases in
Vero cell cytotoxicity after growth of the strains in the presence of
mouse intestinal mucus. We assessed the level of cytotoxicity for
Vero cells of E32511/HSC culture supernatants after growth in
LB broth with MSPIM. E32511/HSC is an O157:NM isolate
that produces SLT-IIc only (9) and grows as well as B2F1 in
MPSIM (15). The cytotoxicity in culture supernatants of
E32511/HSC was not increased after growth in LB with MP-
SIM (Table 2).
We next assessed the level of cytotoxicity for Vero cells in
culture supernatants or lysates from strains 86-24 and B2F1
that were grown in LB broth or LB broth with mouse colonic
mucus. Strain 86-24 is an O157:H7 isolate that produces
SLT-II (8). Colonic mucus rather than MPSIM was used be-
cause 86-24 does not grow well in MPSIM (19a). The cytotox-
icity of SLT-II from 86-24 was not appreciably increased after
growth in the presence of mouse colonic mucus, but the cyto-
toxicity of the SLT(s) from B2F1 was markedly increased (Ta-
ble 2).
SLT antigen levels in B2F1 culture supernatants after
growth in mouse intestinal mucus. The higher levels of toxicity
in culture supernatants of B2F1 after growth in LB supple-
mented with either mouse small-intestinal or colonic mucus
than in culture supernatants from B2F1 grown in LB suggested
either that mouse intestinal mucus serves as a signal to B2F1 to
up-regulate toxin expression, that there is direct activation of
the toxin by a factor in the mucus, or that there is more SLT
secreted in the presence of the mucus. If mouse intestinal
mucus does serve as a signal to increase production of SLT
from B2F1, then a concurrent increase in the level of toxin
antigen should be detectable. We first attempted to measure
the toxin antigen levels by an immunoblot procedure (16), and
on the basis of results obtained with that method, we reported
in an abstract that we had detected an increase in SLT antigen
content (19). Subsequently, we found that there was cross-
reactivity between mouse intestinal mucus in our samples and
the secondary antibody used to detect the mouse monoclonal
primary antibody in the immunoblot protocol. To readdress
the question of whether there was more toxin antigen in the
B2F1 cultures grown in the presence of mouse intestinal mu-
cus, we measured SLT antigen levels by ELISA and by native
PAGE of culture supernatants followed by Western blot anal-
ysis. Both the ELISA and the Western analysis showed that the
toxin antigen contents in LB- or mucus-grown B2F1 cultures
were essentially equivalent (data not shown). These findings
strongly suggest that the increased cytotoxicity of the B2F1
culture supernatant or lysates after growth in mouse intestinal
mucus is due to an activation of one or both of the B2F1 toxins,
SLT-IIvha and SLT-IIvhb.
Activation of crude SLT preparations by MPSIM. To test
the hypothesis that a direct activation of SLT(s) from B2F1
occurs in the presence of mouse intestinal mucus, culture su-
pernatant from B2F1 grown in LB was incubated in the pres-
ence of mouse intestinal mucus diluted in HEPES buffer or
HEPES buffer alone for 4 h at 378C. The cytotoxicity for Vero
cells of the bacterium-free culture supernatant of B2F1 incu-
bated with MPSIM was significantly higher than when the
culture supernatant was incubated with HEPES alone (Fig. 1).
This observation supports our supposition from the SLT anti-
gen level experiments that the mucus-promoted elevated cyto-
toxicity reflects an increase in the activity of SLT-IIvha or
SLT-IIvhb or both toxins. The increased cytotoxicity of SLT(s)
after incubation with MPSIM will hereafter be referred to as
activation.
We next determined if incubation with MPSIM had an effect
on the cytotoxicity of toxin present in the supernatants from
other EHEC isolates. Supernatants of LB-grown cultures of
B2F1, three O157 isolates (86-24, E32511/HSC, and 933D),
and the O139 edema disease isolate S1191 were incubated with
MPSIM or HEPES buffer. The CD50 per milliliter for Vero
cells of the treated supernatants was then determined. Only
supernatant from B2F1 exhibited greater toxicity after incuba-
tion with MPSIM than after incubation with HEPES buffer
(Fig. 1). The fact that only B2F1 supernatant showed this
increase indicated either (i) that there is a component present
in B2F1 supernatant in addition to toxin that is critical for toxin
activation and that this putative component is absent from
TABLE 2. Ratios of cytotoxicity of supernatants or lysates of
EHEC strains grown in LB supplemented with mouse intestinal
mucus to the cytotoxicity after growth in LB alone
Strain
Fold increasea in cytotoxicity (range, n) following
growth in mouse mucus isolated from:
Proximal small intestine Colon
B2F1 36.6b (3.1–672, 12) 362b (317.6–1,666.7, 3)
E32511/HSC 1.2c (0.4–3.1, 4) NDd
86-24 ND 2.5c (1–3.9, 4)
a Calculated by the following formula: (CD50/CFU in LB with mucus)/(CD50/
CFU in LB).
b Geometric mean.
c Arithmetic mean.
d ND, not determined.
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other EHEC strains or (ii) that the toxins from B2F1 are
uniquely activatable by MPSIM. To determine if the B2F1
toxins in the absence of the B2F1 background have the capac-
ity to be activated, culture supernatants containing SLT-IIvha
from DH5a(pSQ343) or SLT-IIvhb from DH5a(pSQ544)
were incubated with MPSIM or HEPES. The level of cytotox-
icity associated with the supernatants after these treatments
was then measured on Vero cells. The CD50 per milliliter of
each toxin culture supernatant incubated with MPSIM was at
least 10-fold higher than the cytotoxicity of the respective cul-
ture supernatant incubated with HEPES alone (Fig. 2). These
data indicate that there is no B2F1 cofactor required for toxin
activation.
Next, supernatants from bacteria containing recombinant
plasmids expressing either SLT-II or SLT-IIc from strain
E32511 or recombinant plasmids expressing one of the three
SLTs from mouse-virulent strain H414-36/89 were tested for
the capacity to be activated. Only supernatants from two of the
toxin genes cloned from H414-36/89 [DH5a(pSQ47) or
DH5a(pSQ135)] were activated (Fig. 2). For a toxin to be
classified as an activatable toxin, the mucus-treated toxin prep-
aration had to have an average (after three or more experi-
ments) of at least a 10-fold increase in Vero cell cytotoxicity
compared with the HEPES-treated toxin preparation. That
only some SLTs were activated indicates that there must be
specific attributes of the toxins produced by these recombinant
plasmids that are necessary for activation.
Activation of purified SLTs. Next, we tested whether puri-
fied toxins can be activated. Purified SLT-I, SLT-II, or SLT-
IIvhb was incubated with MPSIM or HEPES buffer for 1 h at
378C, and the CD50 per milliliter for Vero cells was deter-
mined. The cytotoxicity of SLT-IIvhb was activated more than
1,000-fold in the presence of MPSIM, whereas the cytotoxicity
of SLT-II decreased somewhat (Fig. 3). The reason for the
decrease in the cytotoxicity of SLT-II is not known. The cyto-
toxicity of SLT-I increased approximately sevenfold after in-
cubation with MPSIM (Fig. 3), an observation that suggests
that SLT-I has a slight capacity to be activated or that the toxin
is less stable after dilution into HEPES buffer than after dilu-
tion into mucus. We favor the latter hypothesis because the
SLT-I present in the culture supernatant from strain 933D was
not activated in the presence of mouse intestinal mucus (Fig.
1). To determine if activation was specifically due to mouse
intestinal mucus, purified SLT-I or SLT-IIvhb was incubated
with bovine serum albumin (BSA) or HEPES buffer at 378C
for 2 h, and the CD50 per milliliter for Vero cells was mea-
sured. The cytotoxicity of the purified toxins was not altered by
the presence of the BSA (data not shown). The fact that
purified SLT-II variant toxin or SLT-II variant toxin present in
bacterial supernatants or extracts is activatable indicates that
the source of the toxin does not alter whether the toxin is
activated or not.
Immunoblot analysis of purified toxins treated with MPSIM
or trypsin. To determine if an observable change in the mo-
lecular weight of the toxin occurred after incubation with MP-
SIM, purified SLT-IIvhb that had been incubated with either
MPSIM or HEPES buffer was subjected to SDS-PAGE fol-
lowed by immunoblotting with polyclonal antisera to toxin
purified from B2F1 (32). SLT-IIvhb that had been incubated
with MPSIM showed a shift in molecular weight (Fig. 4A) that
was consistent with cleavage of the A subunit to the A1 frag-
ment. This result suggests that mouse intestinal mucus has the
capacity to nick the SLT-IIvhb A subunit. Although the size of
FIG. 1. Activation of SLT from EHEC strains. Culture supernatant from the
EHEC isolates after growth in LB broth was incubated with MPSIM or HEPES
buffer at 378C for 2 to 4 h, and the CD50 per milliliter was determined on Vero
cells. The data are presented as the ratio of the CD50 of the supernatant after
incubation with MPSIM to the CD50 of the supernatant after incubation with
HEPES buffer. The ratios are the averages from three or more experiments. The
toxins produced by these strains are as follows: B2F1, SLT-IIvha and SLT-IIvhb;
E32511/HSC, SLT-IIc; S1191, SLT-IIe; 86-24, SLT-II; and 933D, SLT-I.
FIG. 2. Activation of SLT from E. coli K-12 transformed with recombinant
plasmids expressing slt genes. Supernatant from cultures grown in LB broth was
incubated with MPSIM or HEPES buffer at 378C for 2 to 4 h. The CD50 per
milliliter was then determined on Vero cells. The data are presented as the ratio
of the Vero cell CD50 in the supernatant after incubation with MPSIM to the
Vero cell CD50 in the supernatant after incubation with HEPES buffer. The
ratios are the averages from three or more experiments. The toxin types pro-
duced from these plasmids are as follows: pSQ544, SLT-IIvhb; pSQ343, SLT-
IIvha; pSQ135, SLT-II variant; pSQ47, SLT-II variant; pSQ81, SLT-II;
pCKS120, SLT-IIc; and pCKS123, SLT-II.
FIG. 3. Activation of purified SLTs. Purified SLT was incubated with MP-
SIM or HEPES buffer for 1 to 2 h at 378C. The Vero cell CD50 per milliliter was
then measured. The data are presented as the ratio of cytotoxicity of the SLT
preparation after incubation with MPSIM to the cytotoxicity after incubation
with HEPES buffer. The ratios represent the averages from five or more exper-
iments.
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the A1 fragment appeared to be the same as the size of the A1
seen in the HEPES- or trypsin-treated toxin (Fig. 4A), these
results do not rule out the possibility that the mucus-nicked
toxin was cleaved at a slightly different site.
To determine if nicking is sufficient for activation, purified
SLT-IIvhb was incubated with trypsin or HEPES buffer. The
CD50 per milliliter was then measured, and a sample of the
trypsin- or HEPES-treated material was subjected to SDS-
PAGE followed by immunoblotting as described above. Tryp-
sin-treated toxin showed a similar shift from the intact A sub-
unit to the A1 subunit (Fig. 4A). The A2 subunit was not
evident in the blot, either because it was unstable under SDS-
PAGE conditions or because it was not recognized by the
antiserum. However, the Vero cell cytotoxicities of the trypsin-
treated toxin and the HEPES-treated toxin were the same,
whereas the MPSIM-treated toxin was 667-fold more cytotoxic
for Vero cells than the HEPES-treated toxin. The trypsin-
treated toxin was still cytotoxic because the disulfide bond that
links A1 and A2 was not reduced prior to addition of the toxin
to Vero cells. When the trypsin-treated toxin was next incu-
bated with MPSIM or HEPES buffer, the MPSIM-treated,
trypsin-nicked toxin was activated 167-fold. That the trypsin-
treated toxin had activity equivalent to that of HEPES-treated
toxin and could subsequently be activated provides evidence
that nicking is not sufficient for activation. Additional support
for our conclusion that nicking is not sufficient for activation is
the finding that SLT-II is nicked (Fig. 4B), but not activated
(Fig. 3), by MPSIM. These findings do not address the ques-
tion of whether nicking is necessary for SLT-IIvha and SLT-
IIvhb activation.
Activation of SLTs with human colonic mucus. To evaluate
whether human colonic mucus could activate SLTs, bacterial
supernatants or purified SLT-I, SLT-II, or SLT-IIvhb was in-
cubated with human colonic mucus or HEPES buffer for 2 h at
378C. The cytotoxicity of each of the samples was then mea-
sured on Vero cells. The results obtained with human colonic
mucus paralleled the findings with mouse intestinal mucus in
five areas. First, supernatants containing SLT-IIvha and SLT-
IIvhb, or an SLT-II variant, and purified SLT-IIvhb were ac-
tivated by the human colonic mucus (Table 3). Second, puri-
fied SLT-IIvhb A subunit was nicked in the presence of the
human mucus (data not shown). Third, supernatants from
strains that produce SLT-I, SLT-II, SLT-IIc, or SLT-IIe were
not activated (Table 3). Fourth, purified SLT-I appeared to be
activated in one of three experiments (Table 3). However, as
with the murine mucus, we believe that SLT-I is probably not
activated because the SLT-I found in supernatants from 933D
or DH5a(pNAS13) was not affected by mucus. Fifth, purified
SLT-II was also not activated by the human colonic mucus
(Table 3), although, as with the mouse mucus, there appeared
to be a decrease in the cytotoxicity of SLT-II after incubation
with human colonic mucus.
Bacterial counts, associated cytotoxicity, and SLT antigen
levels in mouse intestinal contents, serum, and kidney extracts
of mice fed B2F1.Our current in vitro data and previous in vivo
results support a model whereby SLTs from B2F1 encounter
mouse intestinal mucus in vivo, are activated in the gut, and are
then delivered systemically, causing kidney damage and death.
To test this model, we investigated how many B2F1 organisms
could be recovered at various sites of the intestine after oral
feeding of B2F1 and whether associated free SLT was present
in the intestine, serum, or kidneys.
In a preliminary experiment, two mice were fed approxi-
mately 104 B2F1 cells. After 20 h of infection, approximately
105 to 106 B2F1 cells were recovered from the proximal small
intestine, and 107 to 108 B2F1 cells were isolated from the
distal small intestine. However, unlike the colonic and cecal
contents from the mice, the proximal- and distal-small-intesti-
nal contents were not cytotoxic for Vero cells. For subsequent
experiments, we chose to test the distal rather than the prox-
imal small intestine for SLT because 10- to 100-fold more
bacteria were recovered from that site.
In a subsequent set of experiments, two groups of five mice
were fed approximately 4 3 109 B2F1 cells, their blood, kid-
neys, and intestines were removed 9 h or 4 days later, and the
number of B2F1 found in the blood, kidneys, or intestine was
enumerated (Fig. 5A). As controls, two groups of five mice
were fed sucrose alone. No B2F1 cells were recovered in the
blood or kidneys 9 h postinfection. We did not test the 4-day
blood or kidney samples for B2F1, but previous experiments
revealed that even after 5 days of infection, no B2F1 cells are
found in the blood or kidneys of the infected mice (data not
shown). The number of B2F1 recovered from the distal small
intestine was approximately 107 CFU/10-cm segment after 9 h
or 4 days (Fig. 5A). The numbers of bacteria recovered from
the cecum or 10-cm colonic segments were approximately 109
FIG. 4. Immunoblot of SDS-PAGE analysis of SLTs incubated with MPSIM
or trypsin. (A) Purified SLT-IIvhb was treated with MPSIM, HEPES, or trypsin
and incubated at 378C for 2 h. The samples were separated by SDS-PAGE on a
12% gel and then subjected to immunoblot analysis as described in Materials and
Methods. Lane 1, SLT-IIvhb treated with HEPES; lane 2, SLT-IIvhb treated with
MPSIM; lane 3, SLT-IIvhb treated with trypsin; lane 4, SLT-IIvhb treated with
HEPES. (B) Purified SLT-II was treated with MPSIM or HEPES and incubated
at 378C for 2 h. Lane 1, SLT-II treated with MPSIM; lane 2, SLT-II treated with
HEPES. The numbers at the left indicate molecular masses of protein standards
(in kilodaltons).
TABLE 3. Activation of SLTs by human colonic mucus
SLT type
Fold activationa
HCMb prepn 1 HCM prepn 2 Avg
Purified toxin
SLT-IIvhb 14, 20 7, 25 16.5c
SLT-II 0.1 0.7 NDd
SLT-I 10 1, 1.5 ND
Culture supernatant
SLT-IIvha and SLT-IIvhb 10, 10, 100, 23.3 11.7, 25, 50 23e
SLT-II variant 8.75, 8.3 16.7, 8.6 10.6c
SLT-II 0.5, 0.3, 1.25 0.3, 0.6 0.6c
SLT-IIc 0.7, 0.3 1.2, 0.15 0.6c
SLT-IIe 10, 7, 3 2.25, 1.4, 1.2 3e
SLT-I 1.5, 1 0.4, 0.1, 1.2 0.8c
a Calculated as (toxin CD50 after treatment with human colonic mucus)/(toxin
CD50 after treatment with HEPES).
b HCM, human colonic mucus.
c Arithmetic mean of the data from four or more measurements from the two
preparations.
d ND, not determined. The average was not calculated if fewer than three
activation experiments were done.
e Geometric mean of the data from four or more measurements from the two
preparations.
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CFU after 9 h and approximately 1010 CFU after 4 days (Fig.
5A). No B2F1 organisms were recovered from the mice fed
sucrose alone.
We then assessed the cytotoxicity for Vero cells of total
intestinal contents that had been disrupted with a stomacher
(Fig. 5B). No cytotoxicity was detected in the distal small
intestine after 9 h of infection, whereas after 4 days, only one
mouse had high levels of Vero cell cytotoxicity in the distal
small intestine. However, Vero cell cytotoxicity was detected in
sonic lysates of bacteria recovered from three of five of the
distal-small-intestine samples from the 4-day group (data not
shown), which indicates that B2F1 produces SLT while present
in the distal small intestine. By 9 h postinfection, significant
Vero cell cytotoxicity was recovered from the cecum but not
the colon. Four days after infection, both the cecum and the
colon had high levels of associated Vero cell cytotoxicity. We
were also able to detect SLT antigen by ELISA from the
intestinal samples (data not shown).
We next attempted to detect SLT in serum and kidney sam-
ples from the mice by the Vero cell assay and ELISA. We were
unable to detect SLT in the serum by either assay (data not
shown). Kidney extracts from both infected and uninfected
mice were toxic at low dilutions, and no toxicity was detected
at dilutions above 1:50. Thus, we were unable to determine
whether there was low-level Vero cell SLT toxicity. Further-
more, no SLT antigen was detected in the kidney extracts by
ELISA. However, we found that when kidney extracts from
uninfected mice were incubated with crude SLT, we also could
not detect the SLT antigen in the kidney sample (data not
shown). One interpretation of our inability to detect toxin
antigen in SLT-spiked kidney samples is that SLT bound the
ubiquitous Gb3 receptors in that organ (33) and was then
unavailable for recognition by antibody.
Comparison of mouse colonization capacities of B2F1 and
E32511/HSC. The observation that the toxins from B2F1 are
activatable but the toxin from E32511/HSC is not, taken with
the fact that both organisms can grow in MPSIM (15), suggests
that the difference in virulence between these strains is attrib-
utable to the selective activation of the toxins from B2F1.
However, the capacity to grow in MPSIM in vitro may not
completely correlate with the capacity to colonize the mouse
gut in vivo. Therefore, the levels of colonization of the strep-
tomycin-treated mouse intestine after oral feeding of B2F1 or
E32511/HSC were compared. Streptomycin-treated mice were
fed approximately 5 3 106 CFU of B2F1 or E32511/HSC, and
colonization of the intestines was determined 14 h later. B2F1
and E32511/HSC colonized the streptomycin-treated mouse
intestine equally well (Fig. 6).
DISCUSSION
In this study, we found that the SLT-II variant toxins en-
coded by mouse-virulent EHEC strains B2F1 and H414-36/89
become activated, that is, more cytotoxic for Vero cells after
incubation with mouse or human intestinal mucus. To deter-
mine which SLT amino acids might be important for activa-
tion, we compared the amino acid sequences of the activatable
toxins, SLT-IIvha and SLT-IIvhb from B2F1, with the closely
related but not activatable toxin, SLT-IIc from E32511/HSC.
The sequence of the mature B subunits are identical among
SLT-IIc, SLT-IIvha, and SLT-IIvhb. Therefore, the amino ac-
ids important for activation must be present in the A subunit.
Both SLT-IIvha and SLT-IIvhb contain three amino acids that
are different from SLT-IIc in the A subunit (Table 4). Because
two of the three amino acids are the same in SLT-IIvha and
SLT-IIvhb, one or both of these amino acids, serine at position
291 and glutamic acid at position 297 of the mature A subunit
(which has a total of 297 amino acids), are probably important
for activation.
Mucus not only activated SLT-IIvha and SLT-IIvhb but also
cleaved the A subunit of purified SLT-IIvhb into a fragment
with the apparent size of A1. Although nicking purified SLT-
IIvhb with trypsin also generated a fragment with the apparent
FIG. 5. Bacterial counts and associated cytotoxicity of mouse intestinal con-
tents 9 h or 4 days after oral feeding of B2F1. Two groups of five mice each were
fed 4 3 109 B2F1 cells, and the number of bacteria and Vero cell cytotoxicity of
the entire cecum or 10-cm intestinal segments of the distal small intestine (SI) or
colon were determined after disruption of the segments with a stomacher. (A)
Log10 CFU recovered from intestinal segments of mice fed B2F1; (B) Vero cell
cytotoxicity of intestinal contents of mice fed B2F1. The data are geometric
means with 2 standard errors of the mean.
FIG. 6. Bacterial counts in mouse intestines after oral feeding of B2F1 or
E32511/HSC. Groups of five mice were fed approximately 5 3 106 B2F1 or
E32511/HSC cells, the number of bacteria in the cecum, colon, or 10-cm seg-
ments of the proximal or distal small intestine (SI) was enumerated after dis-
ruption of the sample with a stomacher, and serial dilutions of the sample were
plated on LB agar. The data are geometric means plus or minus 2 standard errors
of the mean.
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size of A1, the toxin was not activated. Because trypsin-nicked
SLT-IIvhb had the capacity to subsequently be activated by
MPSIM, we believe that a mechanism other than cleavage
from A to A1 and A2 is responsible for the activation of SLT-
IIvha and SLT-IIvhb by MPSIM. Additional support for the
theory that cleavage and activation by MPSIM are indepen-
dent events is the observation that prenicking of Shiga toxin or
SLT-I with trypsin also does not increase the cytotoxicity of
those toxins for Vero cells (3, 13).
Since activation required preincubation with mucus and mu-
cus alone was not toxic to Vero cells, we believe that the mucus
somehow modifies the toxin to make it more cytotoxic. Al-
though we did not observe a change in the molecular weight of
the A1 peptide in the immunoblot (Fig. 4), we probably would
not have detected a subtle alteration in molecular weight under
the SDS-PAGE conditions used. Alternatively, mucus modifi-
cation may involve the A2 peptide since the amino acid differ-
ences between the activatable and nonactivatable toxins occur
in the A2 peptide. In this study, we could not address possible
effects of mucus on the A2 peptide because it was not detected
in our immunoblots.
Although the crystal structure of Shiga toxin has been solved
(6), the last four amino acids of the A2 fragment were not
placed into the structure because they could not be clearly
resolved. However, recent genetic studies suggest that the last
six amino acids of the Shiga toxin A subunit extend beyond the
B pentamer (12). Moreover, the A subunits of SLT-II, SLT-
IIvha, SLT-IIvhb, and SLT-IIc are four amino acids longer at
the C terminus than is Shiga toxin. These terminal amino acids
may extend out of the B pentamer of the toxin, in a manner
analogous to E. coli heat-labile toxin (29). Thus, the two amino
acid residues that we identified in SLT-IIvha and SLT-IIvhb
that are potentially important for activation may be external to
the B pentamer and, therefore, available as a substrate for the
activating factor(s) that is present in mouse and human intes-
tinal mucus. Additionally, since these two residues are remote
from the active site of the toxin, activation by mouse intestinal
mucus probably does not affect the enzymatic activity of this
toxin. Rather, activation probably affects cytotoxicity by alter-
ing another activity of the toxin, such as trafficking of toxin in
the eukaryotic cell.
Of the EHEC strains that we have fed to streptomycin-
treated mice, only B2F1 and H414-36/89 have LD50s of less
than 10 CFU, and only toxins from these strains are activat-
able. This correlation suggests that the presence of an activat-
able toxin is a requisite for the low mouse LD50s exhibited by
these strains. On the basis of this hypothesis, we propose a
model for the pathogenesis in orally infected streptomycin-
treated mice of EHEC strains B2F1 and H414-36/89 and
EHEC strains with LD50s of $10
10 CFU, such as E32511/HSC
or 86-24 (Fig. 7). The bacteria are ingested and colonize the
small and/or large bowel, where they produce SLT (this study
and reference 15). The SLTs produced by B2F1 and H414-
36/89 become activated, but the SLTs produced by E32511/
HSC and 86-24 do not (this study). Colonization of the small
intestine leads to toxin production and systemic delivery of
SLT as a result of the highly absorptive nature of this part of
the intestine. In support of this systemic delivery hypothesis is
the observation that passive intraperitoneal immunization with
anti-SLT-II antibodies protects the animals from kidney pa-
thology and death. The systemically delivered toxin collects in
sites where Gb3 is found in the mouse such as the renal tubule
cells (33). The kidney damage caused by the toxin, perhaps in
conjunction with cytokines (35), leads to the death of the
mouse (15, 37).
The fact that the only human clinical EHEC isolates that are
mouse lethal at doses of less than 101 CFU express an activat-
able toxin indicates that the presence of an activatable SLT
may be required for the mouse lethality of clinical EHEC
isolates. In contrast, streptomycin-treated mice fed K-12 strains
transformed with recombinant plasmids expressing SLT-II or
SLT-II variant toxins from strains of human origin (with or
without the S291 and E297) are mouse lethal only if they
produce relatively high levels of SLT (16, 22, 37). Paton et al.
also reported that differences in A-subunit amino acids con-
tribute to differences in mean time to death in streptomycin-
treated mice (22), a result which is consistent with our finding
that differences in A subunit amino acids have an effect on
mouse virulence.
We found the S-291 and E-297 in a few other SLT-II variant
toxins when we performed a BLASTP search (1) of the peptide
sequence databases in the National Center for Biotechnology
Information. The SLT-II variants identified in the search in-
cluded those produced by Citrobacter freundii (27), EHEC
strain 7279, an EHEC strain of the O111:H2 serotype (24), an
SLT-producing OX3:H21 strain from a patient with sudden
infant death syndrome (23, 24), and SLT-IIe from pig edema
disease-producing E. coli strains. Although SLT-IIe does have
S-291 and E-297, it was not activated by mouse intestinal mu-
cus (Fig. 2). This failure to activate may reflect the many other
amino acid differences between SLT-IIe and the activatable
toxins SLT-IIvha and SLT-IIvhb. SLT-IIe has other biological
differences from most SLT-II variants; indeed, SLT-IIe binds
preferentially to the receptor Gb4, whereas SLT-IIvha and
SLT-IIvhb bind Gb3 (25). The fact that SLT-IIe was not acti-
vatable shows that the mere presence of S-291 and E-297 in the
A subunit is not sufficient for SLT-II-related activation. We
FIG. 7. Model of toxin delivery. Only the location of the SLT is shown, but
the EHEC strain would be found in the same sites as the SLT. The SLT is shown
as either activated or not activated. We cannot measure ratios of activated SLT
to not activated SLT.
TABLE 4. Amino acid differences in the A subunits of SLT-IIc,
SLT-IIvha, and SLT-IIvhb
Toxin Amino acid sequencedifferencesa
SLT-IIc..................................................................S19, V252, F291, K297
SLT-IIvha..............................................................T19, V252, S291, E297
SLT-IIvhb .............................................................S19, M252, S291, E297
a The amino acid positions given are for the mature A subunit (297 amino
acids). The amino acids that are the same for SLT-IIvha and SLT-IIvhb but
different from those for SLT-IIc are indicated in boldface.
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would predict that (i) the SLT-II variants produced by the
human isolates described above are activatable and (ii) the
strains synthesizing them are highly mouse virulent provided
that the strain can grow in mouse small-intestinal mucus.
The observation that only certain SLTs had the capacity to
be activated by human mucus suggests the possibility that in
EHEC infection of humans, the presence in a strain of an
activatable toxin makes that strain more virulent and/or com-
pensates for the absence of another virulence attribute. For
example, the absence in B2F1 of the genes for induction of the
attaching and effacing lesion may be counterbalanced by the
fact that the SLTs from B2F1 have the capacity to be activated.
In contrast, SLT-I and SLT-II did not appear to be activated by
human or mouse intestinal mucus, but these toxins are linked
to EHEC illnesses in humans. Thus, activation of an SLT per
se is not required for SLT to cause disease.
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